The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts
Abstract
:1. Introduction
2. Recent PDE5 Inhibitors in the Treatment of Erectile Dysfunction
2.1. Sildenafil
2.2. Vardenafil
2.3. Tadalafil
2.4. Avanafil
2.5. Udenafil
2.6. Mirodenafil
2.7. Lodenafil
3. Intra-Cavernous, Transurethral or Topical Administration of Vasoactive Drugs: Alprostadil
4. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Montorsi, F.; Adaikan, G.; Becher, E.; Giuliano, F.; Khoury, S.; Lue, T.F.; Sharlip, I.; Althof, S.E.; Andersson, K.E.; Brock, G.; et al. Summary of the Recommendations on Sexual Dysfunctions in Men. J. Sex. Med. 2010, 7, 3572–3588. [Google Scholar] [CrossRef] [PubMed]
- Feldman, H.A.; Goldstein, I.; Hatzichristou, D.G.; Krane, R.J.; McKinlay, J.B. Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study. J. Urol. 1994, 151, 54–61. [Google Scholar] [CrossRef]
- Shamloul, R.; Ghanem, H. Erectile dysfunction. Lancet 2013, 381, 153–165. [Google Scholar] [CrossRef]
- Solomon, H.; Man, J.W.; Wierzbicki, A.S.; Jackson, G. Relation of Erectile Dysfunction to Angiographic Coronary Artery Disease. Am. J. Cardiol. 2003, 91, 230–231. [Google Scholar] [CrossRef]
- Montorsi, F.; Briganti, A.; Salonia, A.; Rigatti, P.; Margonato, A.; Macchi, A.; Galli, S.; Ravagnani, P.M.; Montorsi, P. Erectile Dysfunction Prevalence, Time of on-Set and Association with Risk Factors in 300 Consecutive Patients with Acute Chest Pain and Angiographically Documented Coronary Artery Disease. Eur. Urol. 2003, 44, 360–365. [Google Scholar] [CrossRef]
- Kaiser, D.R.; Billups, K.; Mason, C.; Wetterling, R.; Lundberg, J.L.; Bank, A.J. Impaired Brachial Artery Endothelium-Dependent Vasodilation in men with Erectile Dysfunction and no Other Clinical Cardiovascular Disease. J. Am. Coll. Cardiol. 2004, 43, 179–184. [Google Scholar] [CrossRef] [Green Version]
- Kovacs, I.; Csaszar, A.; Toth, J.; Siller, G.; Farkas, A.; Tarjan, J.; Horvath, J.; Koller, A. Correlation Between Flow-Mediated Dilation and Erectile Dysfunction. J. Cardiovasc. Pharmacol. 2008, 51, 148–153. [Google Scholar] [CrossRef]
- Rajfer, J.; Aronson, W.J.; Bush, P.A.; Dorey, F.J.; Ignarro, L.J. Nitric Oxide as a Mediator of Relaxation of the Corpus cavernosum in Response to Non-Adrenergic, Non-Cholinergic Neurotransmission. N. Engl. J. Med. 1992, 326, 90–94. [Google Scholar] [CrossRef]
- Porst, H. The rationale for Prostaglandin E1 in Erectile Failure: A Survey of Worldwide Experience. J. Urol. 1996, 155, 802–815. [Google Scholar] [CrossRef]
- Ottensen, B.; Wagner, G.; Virag, R.; Fahrenkrug, J. Penile erection: Possible Role for Vasoactive Intestinal Polypeptide as a Neurotransmitter. Br. J. Med. 1984, 288, 9–11. [Google Scholar] [CrossRef] [Green Version]
- Küthe, A.; Wiedenroth, A.; Mägert, H.J.; Ückert, S.; Forssmann, W.G.; Stief, C.G.; Jonas, U. Expression of Different Phosphodiesterase Genes in Human Cavernous Smooth Muscle. J. Urol. 2001, 165, 280–283. [Google Scholar] [CrossRef] [PubMed]
- Kotera, J.; Mochida, H.; Inoue, H.; Noto, T.; Fujishige, K.; Sasaki, T.; Kobayash, I.T.; Kojima, K.; Yee, S.; Yamada, Y.; et al. Avanafil, a Potent and Highly Selective Phosphodiesterase 5 Inhibitor for Erectile Dysfunction. J. Urol. 2012, 188, 668–674. [Google Scholar] [CrossRef] [PubMed]
- Mulhall, J.P.; Burnett, A.L.; Wang, R.; McVary, K.T.; Moul, J.W.; Bowden, C.H.; di Donato, K.; Shih, W.; Day, W.W. A phase 3, Placebo Controlled Study of the Safety and Efficacy of Avanafil for the Treatment of Erectile Dysfunction after Nerve Sparing Radical Prostatectomy. J. Urol. 2013, 189, 2229–2236. [Google Scholar] [CrossRef] [PubMed]
- Kalsi, J.S.; Kell, P.D. Update on the Oral Treatments for Male Erectile Dysfunction. Eur. Acad. Dermatol. Venereol. 2004, 18, 267–274. [Google Scholar] [CrossRef]
- Emanu, J.C.; Avildsen, I.K.; Nelson, C.J. Erectile Dysfunction after Radical Prostatectomy: Prevalence, Medical Treatments, and Psychosocial Interventions. Curr. Opin. Support. Palliat. Care. 2016, 10, 102–107. [Google Scholar] [CrossRef]
- Stridh, A.; Pontén, M.; Arver, S.; Kirsch, I.; Abé, C.; Jensen, K.B. Placebo Responses among Men with Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis. JAMA Netw. Open 2020, 3, e201423. [Google Scholar] [CrossRef] [Green Version]
- Gul, M.; Carvajal, A.; Serefoglu, E.C.; Minhas, S.; Salonia, A. European Association of Urology Guidelines for Sexual and Reproductive Health 2020: What is New? Int. J. Impot. Res. 2020. [Google Scholar] [CrossRef]
- Lowe, G.; Costabile, R.A. Ten (10) year Analysis of Adverse Event Reports to the Food and Drug Administration for Phosphodiesterase (PDE) Type 5 Inhibitors. J. Sex. Med. 2012, 9, 265–270. [Google Scholar] [CrossRef]
- Jackson, G.; Rosen, R.C.; Kloner, R.A.; Kostis, J.B. The Second Princeton Consensus on Sexual Dysfunction and Cardiac Risk: New Guidelines for Sexual Medicine. J. Sex. Med. 2006, 3, 28–36. [Google Scholar] [CrossRef] [PubMed]
- Yafi, F.A.; Sharlip, I.D.; Becher, E.F. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction. Sex. Med. Rev. 2018, 6, 242–252. [Google Scholar]
- Ismail, E.A.; El-Sakka, A.I. Innovative Trends and Perspectives for Erectile Dysfunction Treatment: A systematic review. Arab. J. Urol. 2016, 14, 84–93. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Greco, E.A.; Spera, G.; Aversa, A. Combining Testosterone and PDE5 Inhibitors in Erectile Dysfunction: Basic Rationale and Clinical Evidences. Eur. Urol. 2006, 50, 940–947. [Google Scholar] [CrossRef] [PubMed]
- Carson, C.C.; Burnett, A.L.; Levine, L.A.; Neha, A. The Efficacy of Sildenafil Citrate (VIAGRA) in Clinical Populations: An update. Urology 2002, 60 (Suppl. 2), 12–27. [Google Scholar] [CrossRef]
- Bischoff, E.; Mondritzki, T.; Niewoehner, U.; Haning, A.; Zimmer, D. Vardenafil Improved Erections in Rabbits Longer than Expected from Plasma Half-Life. Int. J. Impot. Res. 2002, 14 (Suppl. 4), S42. [Google Scholar]
- Young, J.; Auerbach, S.; Prost, H. Vardenafil, a New Selective PDE5 Inhibitor, Significantly Improved all IIEF Domains and Showed Favourable Safety Profile in Patients with Erectile Dysfunction over 12 Weeks. J. Urol. 2001, 165 (Suppl. 5), 224. [Google Scholar]
- Stief, C.G.; Porst, H.; Saenz de Tejada, I.; Ulbrich, E.; Beneke, M.; The Vardenafil Study Group. Sustained Efficacy and Tolerability with Vardenafil over Two Years of Treatment in Men with Erectile Dysfunction. Int. J. Clin. Pract. 2004, 58, 230–239. [Google Scholar] [CrossRef]
- Thadani, U.; Smith, W.; Nash, S.; Bittar, N.; Glasser, S.; Narayan, P.; Stein, R.A.; Larkin, S.; Mazzu, A.; Tota, R.; et al. The Effect of Vardenafil, a Potent and Highly Selective Phosphodiesterase-5 Inhibitor for the Treatment of Erectile Dysfunction, on the Cardiovascular Response to Exercise in Patients with Coronary Artery Disease. J. Am. Coll. Cardiol. 2002, 40, 2006–2012. [Google Scholar] [CrossRef] [Green Version]
- Brock, G.B.; McMahon, C.G.; Chen, K.K.; Costigan, T.; Shen, W.; Watkins, V.; Anglin, G.; Whitaker, S. Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses. J. Urol. 2002, 168, 1332–1336. [Google Scholar] [CrossRef]
- Porst, H.; Patma-Nathan, H.; Guiliano, F.; Anglin, G.; Varanese, L.; Rosen, R. Efficacy of Tadalafil for the Treatment of Erectile Dysfunction at 24 and 36 Houirs after Dosing: A randomized, Controlled Study. Urology 2003, 62, 121–125. [Google Scholar] [CrossRef]
- Guiliano, F.; Varanese, L. Tadalafil: A Novel Treatment for Erectile Dysfuncion. Eur. Heart J. 2002, 4 (Suppl. H), H24–H31. [Google Scholar] [CrossRef]
- Sussman, D.O. Pharmacokinetics, Pharmacodynamics, and Efficacy of Phosphodiesterase Type 5 Inhibitors. J. Am. Osteopath. Assoc. 2004, 104 (Suppl. 4), S11–S15. [Google Scholar] [PubMed]
- Gebekor, E.; Bethell, S.; Fawcett, L. Selectivity of Sildenafil and other Phosphodiesterase Type 5 Inhibitors against All Human Phosphodiesterase Families. Eur. Urol. 2001, 1 (Suppl. 1), 63. [Google Scholar] [CrossRef]
- Emmick, J.T.; Stuewe, S.R.; Mitchell, M. Overview of the Cardiovascular Effects of Tadalafil. Eur. Heart J. 2002, 4 (Suppl. H), H32–H47. [Google Scholar] [CrossRef] [Green Version]
- Zhao, C.; Kim, S.W.; Yang, D.Y.; Kim, J.J.; Park, N.C.; Lee, S.W.; Paick, J.S.; Ahn, T.Y.; Moon, K.H.; Chung, W.S.; et al. Efficacy and Safety of Avanafil for Treating Erectile Dysfunction: Results of a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial. BJU Int. 2012, 110, 1801–1806. [Google Scholar] [CrossRef]
- Goldstein, I.; McCullough, A.R.; Jones, L.A.; Hellstrom, W.J.; Bowden, C.H.; di Donato, K.; Trask, B.; Day, W.W. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of avanafil in subjects with erectile dysfunction. J. Sex. Med. 2012, 9, 1122–1133. [Google Scholar] [CrossRef]
- Nehra, A.; Swearingen, D.; Dietrich, J.; Peterson, C. Hemodynamic Effects of Co-Administration of Avanafil and Glyceryl Trinitrate. J. Sex. Med. 2006, 3 (Suppl 1), 49. [Google Scholar]
- Segal, R.; Burnett, A. Avanafil for the Treatment of Erectile Dysfunction. Drugs Today 2012, 48, 7–15. [Google Scholar] [CrossRef]
- Zhao, C.; Kim, S.W.; Yang, D.Y.; Kim, J.J.; Park, N.C.; Lee, S.W.; Paick, J.S.; Ahn, T.Y.; Min, K.S.; Park, K.; et al. Efficacy and Safety of Once-Daily Dosing of Udenafil in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled trial. Eur. Urol. 2011, 60, 380–387. [Google Scholar] [CrossRef]
- Park, H.J.; Park, J.K.; Park, K.; Min, K.; Park, N.C. Efficacy of Udenafil for the Treatment of Erectile Dysfunction up to 12 Hours after Dosing: A Randomized Placebo-Controlled trial. J. Sex. Med. 2010, 7, 2209–2216. [Google Scholar] [CrossRef]
- Kang, K.K.; Yu, J.Y.; Yoo, M.; Kwon, J.W. The Effect of DA-8159, a Novel PDE5 Inhibitor, on Erectile Function in the Rat Model of Hypercholesterolemic Erectile Dysfunction. Int. J. Impot Res. 2005, 17, 409–416. [Google Scholar] [CrossRef] [Green Version]
- Paick, J.S.; Ahn, T.Y.; Choi, H.K.; Chung, W.S.; Kim, J.J.; Kim, S.C.; Kim, W.; Lee, S.W.; Min, K.S.; Moon, K.H.; et al. Efficacy and safety of mirodenafil, a New Oral Phosphodiesterase Type 5 Inhibitor, for Treatment of Erectile Dysfunction. J. Sex. Med. 2008, 5, 2672–2680. [Google Scholar] [CrossRef]
- Cho, M.C.; Paick, J.S. A review of the Efficacy and Safety of Mirodenafil in the Management of Erectile Dysfunction. Ther. Adv. Urol. 2016, 8, 100–117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Glina, S.; Fonseca, G.N.; Bertero, E.B.; Damião, R.; Rocha, L.C.; Jardim, C.R.; Cairoli, C.E.; Teloken, C.; Torres, L.O.; Faria, G.E.; et al. Efficacy and Tolerability of Lodenafil Carbonate for Oral Therapy of Erectile Dysfunction: A Phase III Clinical Trial. J. Sex. Med. 2010, 7, 1928–1936. [Google Scholar] [CrossRef]
- Toque, H.A.; Teixeira, C.E.; Lorenzetti, R.; Okuyama, C.E.; Antunes, E.; de Nucci, G. Pharmacological Characterization of a Novel Phosphodiesterase Type 5 (pde5) Inhibitor, Lodenafil Carbonate, on Human and Rabbit Corpus Cavernosum. Eur. J. Pharmacol. 2008, 591, 189–195. [Google Scholar] [CrossRef] [PubMed]
- Hatzimouratidis, K.; Salonia, A.; Adaikan, C.; Buvat, J.; Carrier, S.; El-Meliegy, A.; McCullogh, A.; Torres, L.O.; Kehra, M. Pharmacotherapy for Erectile Dysfunction: Recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2016). J. Sex. Med. 2016, 3, 465–488. [Google Scholar] [CrossRef] [PubMed]
- Sanda, M.G.; Dunn, R.L.; Michalski, J.; Sandler, H.M.; Northouse, L.; Hembroff, L.; Lin, X.; Greenfield, T.K.; Litwin, M.S.; Saigal, C.S.; et al. Quality of Life and Satisfaction with Outcome among Prostate Cancer Survivors. N. Engl. J. Med. 2008, 358, 1250–1261. [Google Scholar] [CrossRef]
- Modh, R.A.; Mulhall, J.P.; Gilbert, S.M. Sexual Dysfunction after Cystectomy and Urinary Diversion. Nat. Rev. Urol. 2014, 11, 445–453. [Google Scholar] [CrossRef] [Green Version]
- Celentano, V.; Cohen, R.; Warusavitarne, J.; Faiz, O.; Chand, M. Sexual Dysfunction Following Rectal Cancer Surgery. Int. J. Colorectal Dis. 2017, 32, 1523–1530. [Google Scholar] [CrossRef]
- Goldstein, I.; Chambers, R.; Tang, W.; Stecher, V.; Hassan, T. Real-World Observational Results from a Database of 48 Million Men in the United States: Relationship of Cardiovascular Disease, Diabetes Mellitus and Depression with Age and Erectile Dysfunction. Int. J. Clin. Pract. 2018, 72, e13078. [Google Scholar] [CrossRef]
- Kizilay, F.; Gal, H.E.; Serefoglu, E.C. Diabetes and Sexuality. Sex. Med. Rev. 2017, 5, 45–51. [Google Scholar] [CrossRef]
- Braun, M.; Wassmer, G.; Klotz, T.; Reifenrath, B.; Mathers, M.; Engelmann, U. Epidemiology of Erectile Dysfunction: Results of the Cologne Male Survey. Int. J. Impot. Res. 2000, 12, 305–311. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Perimenis, P.; Konstantinopoulos, A.; Perimeni, P.P.; Gyftopoulos, K.; Kartsanis, G.; Liatsikos, E.; Athanasopoulos, A. Long-Term Treatment with Intracavernosal Injections in Diabetic Men with Erectile Dysfunction. Asian J. Androl. 2006, 8, 219–224. [Google Scholar] [CrossRef] [PubMed]
- Raina, R.; Lakin, M.M.; Thukral, M.; Agarwal, A.; Ausmundson, S.; Montague, D.K.; Klein, E.; Zippe, C.D. Long-Term Efficacy and Compliance of Intracorporeal (Ic) Injection for Erectile Dysfunction Following Radical Prostatectomy: SHIM (IIEF-5) A-nalysis. Int. J. Impot. Res. 2003, 15, 318–322. [Google Scholar] [CrossRef] [PubMed]
- Costabile, R.A.; Spevak, M.; Fishman, I.J.; Govier, F.E.; Hellstrom, W.J.; Shabsigh, R.; Nemo, K.J.; Rapport, J.L.; Tam, P.Y.; Weldon, K.L.; et al. Efficacy and Safety of Transurethral Alprostadil in Patients with Erectile Dysfunction Following Radical Prostatectomy. J. Urol. 1998, 160, 1325–1328. [Google Scholar] [CrossRef]
- Costa, P.; Potempa, A.J. Intraurethral Alprostadil for Erectile Dysfunction: A Review of the Literature. Drugs 2012, 72, 2243–2254. [Google Scholar] [CrossRef]
- Khan, M.A.; Raistrick, M.; Mikhailidis, D.P.; Morgan, R.J. MUSE: Clinical experience. Curr. Med. Res. Opin. 2002, 18, 64–67. [Google Scholar] [CrossRef]
- Nehra, A.; Blute, M.L.; Barrett, D.M.; Moreland, R.B. Rationale for Combination Therapy of Intraurethral Prostaglandin e1 and Sildenafil in the Salvage of Erectile Dysfunction Patients Desiring Non-invasive Therapy. Int. J. Impot. Res. 2002, 14 (Suppl. 1), S38–S42. [Google Scholar] [CrossRef] [Green Version]
- Mydlo, J.H.; Volpe, M.A.; Macchia, R.J. Initial Results Utilizing Combination Therapy for Patients with a Suboptimal Response to Either Alprostadil or Sildenafil Monotherapy. Eur. Urol. 2000, 38, 30–34. [Google Scholar] [CrossRef]
- Rooney, M.; Pfister, W.; Mahoney, M.; Nelson, M.; Yeager, J.; Steidle, C. Long-Term, Multicenter Study of the Safety and Efficacy of Topical Alprostadil Cream in Male Patients with Erectile Dysfunction. J. Sex. Med. 2009, 6, 520–534. [Google Scholar] [CrossRef]
- Padma-Nathan, H.; Yeager, J.L. An Integrated Analysis of Alprostadil Topical Cream for the Treatment of Erectile Dysfunction in 1732 Patients. Urology 2006, 68, 386–391. [Google Scholar] [CrossRef]
- Cai, T.; Palumbo, F.; Liguori, G.; Mondaini, N.; Scroppo, F.I.; di Trapani, D.; Cocci, A.; Zucchi, A.; Verze, P.; Salonia, A.; et al. The Intrameatal Application of Alprostadil Cream (Vitaros) Improves Drug Efficacy and Patient’s Satisfaction: Results from a Randomized, Two-Administration Route, Cross-over Clinical Trial. Int. J. Impot. Res. 2019, 31, 119–125. [Google Scholar] [CrossRef] [PubMed]
- Zucchi, A.; Costantini, E.; Scroppo, F.I.; Silvani, M.; Kopa, Z.; Illiano, E.; Petrillo, M.G.; Cari, L.; Nocentini, G. The First-Generation Phosphodiesterase 5 Inhibitors and Their Pharmacokinetic Issues. Andrology 2019, 7, 804–817. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Corona, G.; Maggi, M.; Jannini, E.A. Edeus, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior among European Men with a Focus on 2nd Generation Avanafil. J. Sex. Med. 2018, 6, 15–23. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grice, P.T.; Liu, J.; Gabrielson, A.T.; Pearce, I.; Bivalacqua, T.J.; Modgil, V. Drug Delivery Options and Therapeutic Advances in the Management of Erectile Dysfunction. Expert. Opin. Drug. Deliv. 2020, 17, 1259–1268. [Google Scholar] [CrossRef] [PubMed]
Drug Compound | Key Clinical Studies/Integrated Analysis | Key Pharmacological Data | Route of Administration | Product Availability |
---|---|---|---|---|
Sildenafil | Carson, CC; et al. UROLOGY 2002, 60 (Suppl 2): 12–27 [23] | IC50 = 7 nM Tmax (area under the time-concentration curve) = 60 min (after a single dose of 50 mg or 100 mg) T (lambda)0.5 = 4 h | orally active (PDE5 inhibitor) | The Americas, EC, Africa, Asia(-Pacific), Australia |
Vardenafil | Stief, CG; et al. Int J Clin Pract 2004, 58: 230–239 [26] Brock, GB; et al. J Urol 2002, 168: 1332–1336 [28] | IC50 = 0.7 nM Tmax = 0.7 to 1 h (after a single dose of 10 mg or 20 mg) T0.5 = 4 to 5 h | orally active (PDE5 inhibitor) | The Americas, EC, Africa, Asia(-Pacific), Australia |
Tadalafil | Porst, H; et al. UROLOGY 2003, 62: 121–125 [29] | IC50 = 5 nM Tmax = 0.8 to 1.2 h (after a single dose of 20 mg) T0.5 = 18 h | orally active (PDE5 inhibitor) | The Americas, EC, Africa, Asia(-Pacific), Australia |
Avanafill | Mulhall, JP; et al. J Urol 2013, 189: 2229–2236 [13] Zhao, C; et al. BJU Int 2012, 110: 1801–1806 [34] Goldstein, I; et al. J Sex Med 2012, 9: 1122–1133 [35] | IC50 = 5.2 nM Tmax = 30 to 40 min (after a single dose of 100 mg or 200 mg T0.5 = 6 h | orally active (PDE5 inhibitor) | The Americas, EC, Asia(-Pacific) |
Udenafil | Zhao, C; et al. Eur Urol 2011, 60: 380–387 [38] Park, HJ; et al. J Sex Med 2010, 7: 2209–2216 [39] | IC50 = 8.2 nM Tmax = 0.8 to 1 h (after a single dose of 100 mg or 200 mg) T0.5 = 7 to 12 h | orally active (PDE5 inhibitor) | Asia(-Pacific (South Korea only) |
Mirodenafil | Paick, JS; et al. J Sex Med 2008, 5: 2672–2680 [41] Cho, MC; Paick, JS. Ther Adv Urol 2016, 8: 100–117 [42] | IC50 = 0.5 nM Tmax = 60 min (after a single dose of 50 mg or 100 mg) T0.5 = 4 to 5 h | orally active (PDE5 inhibitor) | Asia(-Pacific (South Korea only) |
Lodenafil | Glina, S; et al. J Sex Med 2010, 7: 1928–1936 [43] Hatzimouratidis, K; et al. J Sex Med 2016, 3: 465–488 [45] | IC50 = 0.2 nM Tmax = 1.5 h (after a single dose of 40 mg or 80 mg) T0.5 = 3.3 h | orally active (PDE5 inhibitor) | South Americ (Brazil only) |
Alprostadil (chemically identical to prostaglandin E1) CAVERJECT/EDEX | Perimenis, P; et al. Asian J Androl 2006, 8: 219–224 [52] Raina, R; et al. Int J Impot Res (IJIR) 2003, 15: 318–322 [52] | Compound is administered locally, thus not distributed systemically (see Route of administration) | Intracavernosal route of administration (on-demand self-injection regimen) | The Americas, EC, Africa, Asia(-Pacific), Australia |
Alprostadil (Prostaglandin E1) MUSE | Costabile, RA; et al. J Urol 1998, 160: 1325–1328 [53] Khan, MA; et al. Curr Med Res Opin 2002, 18: 64–67 [56] | Compound is administered locally, thus not distributed systemically (see Route of administration) | intra-/transurethral route of administration | The Americas, EC, Asia(-Pacific), Australia |
Alprostadil (Prostaglandin E1) VITAROS | Rooney, M; et al. J Sex Med 2009, 6: 520–534 [59] Padma-Nathan, H; Yeager, JL. UROLOGY 2006, 68: 386–391 [60] | Compound is administered locally, thus not distributed systemically (see Route of administration) | topical/transdermal route of administration | The Americas (Canada), EC |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kedia, G.T.; Ückert, S.; Tsikas, D.; Becker, A.J.; Kuczyk, M.A.; Bannowsky, A. The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts. J. Clin. Med. 2020, 9, 2987. https://doi.org/10.3390/jcm9092987
Kedia GT, Ückert S, Tsikas D, Becker AJ, Kuczyk MA, Bannowsky A. The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts. Journal of Clinical Medicine. 2020; 9(9):2987. https://doi.org/10.3390/jcm9092987
Chicago/Turabian StyleKedia, George T., Stefan Ückert, Dimitrios Tsikas, Armin J. Becker, Markus A. Kuczyk, and Andreas Bannowsky. 2020. "The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts" Journal of Clinical Medicine 9, no. 9: 2987. https://doi.org/10.3390/jcm9092987
APA StyleKedia, G. T., Ückert, S., Tsikas, D., Becker, A. J., Kuczyk, M. A., & Bannowsky, A. (2020). The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts. Journal of Clinical Medicine, 9(9), 2987. https://doi.org/10.3390/jcm9092987